Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience

Conclusion Bortezomib is a safe and well-tolerated therapy for patients with AL amyloidosis with a rapid hematologic response and cardiac response, as assessed by the NT-proBNP level. Micro-Abstract Bortezomib exhibits unprecedented single-agent activity in AL amyloidosis. Here, we performed a review of the use of bortezomib containing regimens to assess the rapidity and quality of response. After a median of 4 cycles, a HR was seen in 49/52 cases (94.2%) demonstrating that bortezomib is a safe and well-tolerated therapy for AL patients showing rapid HR and cardiac responses.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research